INTRODUCTION {#sec1-1}
============

Globozoospermia (MIM 102530) is a major subtype of teratozoospermia and is a rare but severe causation of male infertility characterized by round-headed spermatozoa.[@ref1] Because acrosomes are impaired or completely lost in globozoospermia, spermatozoa fail to fertilize oocytes.[@ref2] Normal spermatozoa are shaped through spermatid elongation, which is coordinated with the biogenesis of acrosomes. During spermatid elongation or differentiation, Golgi apparatus-derived pro-acrosome vesicles are gathered and attached to the anterior face of the spermatozoa, so failure in either sperm-head elongation or acrosome biogenesis can result in globozoospermia.[@ref3][@ref4][@ref5][@ref6] From animal models and genome sequencing of related patients, many genetic factors have been revealed to be associated with globozoospermia and have been found to be involved in acrosome biogenesis or attachment to the nuclear membranes.[@ref4][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]

*DPY19L2* is highly expressed in the testis and it is a globozoospermia pathogenic gene, which has been identified in globozoospermic patients and validated in animal models. The first case of a *DPY19L2* variant in globozoospermia was a homozygous deletion of 200 kb on chromosome 12, which contains the *DPY19L2* locus. The large-scale deletion led to the complete loss of the *DPY19L2* gene, and the affected sperms were round headed without acrosomes.[@ref13] The DPY19L2 protein is localized on the inner membrane of the sperm nuclear envelope (NE), facing the acrosome and with both its N- and C-terminuses embedded in the nucleoplasm. The inner NE-localized DPY19L2 facilitates the attachment of the acrosome to the NE. In Dpy19l2-deficient mouse spermatids, the development of the acrosome has been found to be hampered as early as step 4 spermatids.[@ref14] Without Dpy19l2, the acrosome matrix is no longer bound tightly to the acroplaxome, and the acrosome extension along the nucleus stops. All these defects result in round-headed spermatozoa.[@ref14]

In addition to the loss of DPY19L2 protein, substitution of certain amino acids in the protein can also lead to globozoospermia. More than ten point variants of *DPY19L2* have been reported in globozoospermic patients, with *DPY19L2* variants showing a relatively high frequency in different cohorts.[@ref15][@ref16][@ref17][@ref18][@ref19] Reported *DPY19L2* variants include nonsense mutations, missense mutations, and deletions of certain nucleotides, resulting in mutated or truncated DPY19L2 proteins. However, most of the studies were performed in European, North African, and Middle Eastern populations, and only one cohort of Chinese patients has been reported.[@ref18] Here, we conducted a systematic survey on a new Chinese cohort of globozoospermic patients and found complete or partial deletion of the *DPY19L2* gene and six additional new point variants. We also found that most of the infertility of the patients could be overcome by intracytoplasmic sperm injection (ICSI) with assisted oocyte activation (AOA). Our results provide new insight into *DPY19L2* variant-associated globozoospermia, which have very important implications for the diagnosis and treatment of this severe male infertility.

PATIENTS AND METHODS {#sec1-2}
====================

 {#sec2-1}

### Patients {#sec3-1}

Globozoospermic patients were recruited from Peking University First Hospital (Beijing, China), Peking University Third Hospital (Beijing China), and The First Affiliated Hospital of Anhui Medical University (Hefei, China). Informed consent was obtained from all individual participants included in the study. Related examinations of their samples are listed in **[Table 1](#T1){ref-type="table"}**. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees of three above mentioned hospitals and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

###### 

Clinical information of the globozoospermic patients

  *Patient*   *Age (year)*   *Semen volume (ml)*   *Sperm concentration (×10^6^ per ml)*   *Total sperm count (×10^6^)*   *Motility PR/NP/IM (%)*   *Sperm morphology (%)*         
  ----------- -------------- --------------------- --------------------------------------- ------------------------------ ------------------------- ------------------------ ----- -----
  P1          35             4                     53                                      212                            19/4/77                   0                        100   100
  P2          35             3                     37                                      111                            8/1/91                    0                        100   100
  P3          31             2                     61                                      122                            11/9/79                   0                        100   100
  P4          35             3                     36                                      108                            34/15/51                  0                        100   100
  P5          35             1                     72                                      72                             17/16/72                  0                        100   100
  P6          30             2                     33                                      66                             49/22/30                  0                        100   100
  P7          24             6                     7                                       42                             12/20/68                  0                        100   100
  P8          25             2                     55                                      110                            17/19/64                  0                        100   100
  P9          33             2                     35                                      70                             14/10/77                  0                        100   100
  Median      33             2                     37                                      108                            16/15/70                  0                        100   100

The sperm motility and the percentages of morphologically normal and abnormal spermatozoa were evaluated according to the guidelines (WHO, 2010). PR: progressive motility; NP: nonprogressive motility; IM: immotility; WHO: World Health Organization

### Morphological examinations of human spermatozoa {#sec3-2}

Semen spermatozoa were spread onto polylysine-coated slides and dried in air, and then fixed by 4% (*w/v*) polyformaldehyde (PFA, Solarbio, Beijing, China). Acrosomes were stained by fluorescein isothiocyanate (FITC)-labeled Peanut agglutinin (PNA, ENZO, Farmingdale, NY, USA), and nuclei were stained by 4', 6-diamidino-2-phenylindole (DAPI, Roche, Basel, Switzerland).

### DNA extraction and DPY19L2 deletion screening {#sec3-3}

Genomic DNA was extracted from blood with DNA extraction kits (DP304), according to the instructions of the manufacturers (TIANGEN, Beijing, China). *DPY19L2* deletion screening primers were designed as previously described.[@ref13] Fifty nanograms genomic DNA, 10 pmol forward and reverse primers, and PCR premix (Yeasen, Shanghai, China) were used in each PCR reaction, and the annealing temperature was the same as that described previously.[@ref13] Each PCR reaction was performed for 35 cycles, and the same amount of products were analyzed with 1.5% (*w/v*) agarose gel (Amresco, Solon, OH, USA).

### Whole-exome sequencing {#sec3-4}

The qualified genomic DNA samples were randomly fragmented by Covaris technology,[@ref20] with the size of the library fragments being mainly distributed between 150 bp and 250 bp. The end repair of DNA fragments was performed and an "A" base was added to the 3' end of each strand. Adapters were then ligated to the A-tailed DNA fragments for amplification and sequencing using Truseq DNA sample preparation (Illumina Inc., San Diego, CA, USA). Size-selected DNA fragments were amplified by ligation-mediated PCR (LM-PCR), purified, and hybridized to the exome array for enrichment using Sure SelectXT Custom kit (Agilent, Santa Clara, CA, USA). Nonhybridized fragments were then washed away and captured products circularized. Rolling circle amplification (RCA) was performed to produce DNA Nanoballs (DNBs). Each resulting qualified captured library was then loaded on a BGISEQ-500 sequencing platform (BGI, Shenzhen, China), and we performed high-throughput sequencing for each captured library to ensure that each sample met the desired average sequencing coverage (globally over 95%) with a depth of ×30. Sequencing-derived raw image files were processed by BGISEQ-500 base-calling software (BGI, Shenzhen, China), using Confirm-Show-All base calling with default parameters. The sequence data of each individual were generated as a paired-end read, which was defined as "raw data" and stored in FASTQ format.

The bioinformatics analysis began with the sequencing data (raw data from the BGISEQ platform). First, clean data were produced by filtering the raw data, and the clean data of each sample were mapped to the human reference genome (GRCh37). Burrows--Wheeler Aligner (BWA) software (<https://github.com/lh3/bwa/archive/v0.7.17.tar.gz>) was used to do the alignment.[@ref21][@ref22] To ensure accurate variant calling, we followed the recommended best practices for variant analysis with the Genome Analysis Toolkit (GATK, <https://github.com/broadinstitute/gatk/archive/4.0.1.1.tar.gz>).[@ref23][@ref24] Local realignment around InDels and base quality score recalibration were performed by GATK, with duplicate reads removed by Picard tools (<https://github.com/broadinstitute/picard/releases/download/2.18.11/picard.jar>). The sequencing depth and coverage for each individual were calculated from the alignments.

In addition, the strict data analysis quality control system (QC) of the whole pipeline was built to guarantee qualified sequencing data. All genomic variations, including single-nucleotide polymorphisms (SNPs) and InDels, were detected by state-of-the-art software, such as Haplotype Caller of GATK (v3.8; Broad Institute, Cambridge, MA, USA). After that, hard-filtering methods were applied to get high-confident variant calls. Next, the Intervar tool (<https://github.com/WGLab/InterVar/archive/v2.0.1.tar.gz>) was applied to perform a series of annotations for variants.[@ref25] The final variants and annotation results were used in the downstream advanced analysis.

### Oocyte activation procedure {#sec3-5}

*In vitro* fertilization (IVF) medium (COOK Medical, Brisbane, Australia) containing 10 mol l^−1^ calcium ionophore (A23187, Sigma-Aldrich, St. Louis, MO, USA) was prepared before ICSI. Thirty minutes after ICSI, oocytes were activated in the prepared IVF medium for 5 min. These oocytes were washed three times in fresh IVF medium without calcium ionophore and then were individually transferred into a drop of IVF medium under mineral oil in disc for incubation at 37°C under 5% (*v/v*) CO~2~ air atmosphere.[@ref26] IVF was considered successful if zygotes presented two pronuclei (2PN) on day 1 (16--18 h after ICSI). On days 3, 5, and 6, the number and quality of embryos were checked and then were classified into different grades.[@ref27][@ref28] On day 5 or 6, fresh or frozen embryos were transferred in the following cycle, respectively.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Confirmation of the globozoospermia of the patients {#sec3-6}

Patients were referred to our center for semen analysis after trying unsuccessfully for a pregnancy for at least 3 years. Semen samples, obtained after 3 days of sexual abstinence, showed nine cases of total globozoospermia (100%). These nine genetically independent patients ranged from 24 to 35 years of age (**[Table 1](#T1){ref-type="table"}**), and the median progressive motility of the spermatozoa was 16% with seven of the nine patients below the WHO 2010 normal threshold.[@ref18] DNA and acrosomes were stained during morphological analysis, with results showing that all the spermatozoa were round headed and lacked normal acrosomes. No other defects in sperm tails were found in the patients, indicating total globozoospermia. Representative images of the spermatozoa are shown in **[Figure 1](#F1){ref-type="fig"}**.

![Representative images of sperm from globozoospermic patients. All the spermatozoa from affected individuals and control individuals were stained with PNA for the acrosome and DAPI for the nucleus. Scale bars = 5 μm. PNA: peanut agglutinin; DAPI: 4', 6-diamidino-2-phenylindole; FITC: fluorescein isothiocyanate; DIC: differential interference contrast microscope; WT: wild type.](AJA-21-183-g001){#F1}

### New variants of DPY19L2 {#sec3-7}

We first screened for *DPY19L2* deletions according to the previously established strategy[@ref13] and amplified seven loci around the DPY19L2 gene (a--g) from genomic DNA (**Supplementary Figure 1a**). The seven loci were successfully amplified in control fertile individuals, and four globozoospermia patients also yielded complete amplification of the loci (P3, P6, P8, and P9 in **Supplementary Figure 1b**). To identify novel variants from globozoospermic patients, we next applied whole-exome sequencing (WES) to the four DPY19L2 nondeleterious globozoospermic patients. To establish the family pedigree of the potential variants, we collected genomic DNA of some patients' parents (P3 and P8). P3 carried a heterozygous nucleotide substitution in intron 21 next to exon 21. Pedigree analysis of the affected family revealed that this variant was maternally inherited (**[Figure 2](#F2){ref-type="fig"}**). The WES results indicated that P6 carried a homozygous variant on exon 18- c.1720C\>T.

###### 

DPY19L2 deletion screening of the globozoospermic patients. (**a**) The distribution of a-g loci on and around *DPY19L2*. (**b**) Genomic DNA was extracted from the blood of the patients and the reported seven loci of *DPY19L2* were amplified. P1, P2, P4, P5, and P7 show complete or partial deletion of the *DPY19L2* gene, while P3, P6, P8, and P9 show no deletion in the *DPY19L2* gene.

###### 

Click here for additional data file.

![Novel *DPY19L2* variants in globozoospermic patients without gene deletion revealed by whole-exome sequencing. P3 carried a heterozygous variant c.2126+5G\>A, which was maternally inherited. P6 carried a homozygous variant c.1720C\>T leading to PTC in DPY19L2 mRNA. P8 contained a compound heterozygous *DPY19L2* variant, paternally inherited c.1182-1184delATC and maternally inherited c.368A\>G. P9 contained two heterozygous variants c.1182-1186delATCTT and c.1553-1554delAT, which are probable compound heterozygous variants. WT: wild type; DPY19L2: dpy-19-like 2; PTC: premature termination codon.](AJA-21-183-g002){#F2}

P8 contained compound heterozygous DPY19L2 variants: one was a three-nucleotide deletion from c.1182-1184 (c.1182-1184delATC), which was paternally inherited, and the other was a nucleotide substitution c.368A\>G, which was maternally inherited. The variant c.1182-1184delATC disrupted the code for Leu394 and Ser395, and the new frame encoded for a Phe without influencing the following coding frame. The final result of this variant was Leu394_Ser395delinsPhe. The A to G substitution at nucleotide 368 resulted in an amino acid change from His to Arg in the protein sequence. P9 also contained a deletion near c.1182, a five-nucleotide deletion from 1182 to 1186 (c.1182-1186delATCTT) that led to a frameshift after Met392 and resulted in a stop code at position 413. P9 also contained a two-nucleotide deletion (c.1553-1554delAT) that led to a frameshift after Tyr518 and resulted in a stop code at position 523. Blood samples of the parents of P9 were unavailable, so it was difficult to determine whether P9\'s two deletions are compound heterozygous variants or not. In summary, the new *DPY19L2* variants found in our cohort led to loss of function in the DPY19L2 protein but not any other new genes. All the newly identified variants are summarized in **[Table 2](#T2){ref-type="table"}**.

###### 

Summary of the new *DPY19L2* variants found in the investigated globozoospermic patients

  *Patients*         *mRNA change*         *Protein change*           *Variant type*          *Max allele frequency*   *GERP (prediction of conservation)*   *Zygosity*
  ------------------ --------------------- -------------------------- ----------------------- ------------------------ ------------------------------------- -----------------------
  P3                 c.2126+5G\>A          \-                         Splice region variant   0                        3.78                                  Heterozygous
  P6                 c.1720C\>T            p.Arg574Ter                Nonsense                0                        2.51                                  Homozygous
  P8                 c.1182_1184delATC     p.Leu394_Ser395delinsPhe   Inframe deletion        \<0.0001                 1.37                                  Compound heterozygous
  c.368A\>G          p.His123Arg           Missense                   0                       2.5                                                            
  P9                 c.1182_1186delATCTT   p.Leu394PhefsTer19         Frame shift             0                        2.71                                  Compound heterozygous
  c.1553_1554delAT   p.Tyr518CysfsTer14    Frame shift                \<0.0001                3.18                                                           

The max allele frequency of the variants was from gnomAD and ExAC databases. Polyphen scores were only suitable to assess the pathogenicity of missense mutations, and the Polyphen score of c.368A\>G is 0.998, which means likely pathogenic. GERP: Genomic Evolutionary Rate Profiling

### Effects of single-nucleotide substitution on the properties of conserved amino acid in the DPY19L2 protein {#sec3-8}

In addition to gene deletions, numerous point mutations of *DPY19L2* have been identified in globozoospermic patients. All the reported mutations and the novel variants found in our study are summarized in **[Figure 3a](#F3){ref-type="fig"}**, which includes 19 mutations. These mutations include nine nonsense mutations, seven missense mutations, and three intronic mutations. We then analyzed the amino acid properties before and after mutation, finding that all the mutations resulted in amino acid property changes, either from polar to nonpolar or from noncharged to charged (**[Figure 3b](#F3){ref-type="fig"}**). Since DPY19L2 is highly conserved among species, we then investigated whether the mutated amino acids were conserved or not (**[Figure 3c](#F3){ref-type="fig"}**). We found that all the affected amino acids were highly conserved among species, with only T493 being less conserved among all species yet still conserved in humans, monkeys, and sheep (**[Figure 3d](#F3){ref-type="fig"}**). These analyses revealed that single-nucleotide substitutions might change the important properties of the conserved amino acids, thus disrupting the function of DPY19L2 protein.

![The mutated *DPY19L2* sites were highly conserved among species. (**a**) The distribution of reported and newly identified variants on DPY19L2 protein. The blue boxes show the predicted transmembrane domains. The variants in black are reported variants, and those in red are newly found variants in our study. (**b**) The amino acid property changes before and after mutations. (**c**) *DPY19L2* is highly conserved among species; the sequences were aligned with DNAMAN. (**d**) The mutated amino acids are conserved among species. The sequences were aligned with Multalign; amino acids in red show high identity among species, those in blue show neutral identity, and those in black show low identity. DPY19L2: dpy-19-like 2.](AJA-21-183-g003){#F3}

### DPY19L2 mutations are the major cause of globozoospermia {#sec3-9}

Although globozoospermia has been well documented, few pathogenic genes have been identified, so we analyzed the percentage of *DPY19L2* mutations together with two other globozoospermia-associated genes spermatogenesis associated 16 (*SPATA16*) and protein interacting with C kinase 1 (*PICK1*) in all reported patients and our current Chinese cohort.[@ref7][@ref8][@ref15][@ref16][@ref17][@ref18][@ref19] We found that in 193 reported globozoospermic patients, over 57% of them carried *DPY19L2* mutations, but less than 5% of the patients carried mutations in *SPATA16* or *PICK1*. Nearly 40% of the patients were diagnosed with globozoospermia due to unknown reasons (**[Figure 4a](#F4){ref-type="fig"}**). In all the patients with *DPY19L2* variants, over 70% carried a gene deletion and about 23% carried point mutations (**[Figure 4b](#F4){ref-type="fig"}**). By comparing reported genetic data from globozoospermic patients of Western countries with reported genetic data from those of China, we found that the frequency of *DPY19L2* variants in Chinese patients is currently higher than that in patients of Western countries (**Figure [4c](#F4){ref-type="fig"}** and **[4d](#F4){ref-type="fig"}**).

![Variants in *DPY19L2* are the major cause of globozoospermia. (**a**) The percentage of known and unknown gene variants in the reported globozoospermic patients from a total of 193 patients from reported cases and the current study was analyzed, among which 111 (57.5%) carried *DPY19L2* variants, 5 (2.6%) carried *SPATA16* variants, 1 (0.5%) carried *PICK1* variant, and the remaining 76 (39.4%) patients carried unknown variants. (**b**) The percentage of gene deletion and point mutations in patients with DPY19L2 dysfunction in a total of 111 patients with *DPY19L2* variants from reported cases and the current study was analyzed, among which 85 (76.6%) carried *DPY19L2* deletions and 26 (23.4%) carried *DPY19L2* point mutations. (**c**) The percentages of *DPY19L2* and other known or unknown gene mutations in currently reported Chinese globozoospermic patients. A total of 24 patients were analyzed, among which 18 (75.0%) of them carried *DPY19L2* mutations and 6 (25.0%) of them carried other mutations. (**d**) The percentages of *DPY19L2* and other known or unknown gene mutations in currently reported globozoospermic patients from Western countries. A total of 169 patients were analyzed, and 88 (52.1%) of them carried *DPY19L2* variants and 81 (47.9%) of them carried other variants. *P* = 0.034 as examined by Chi-squared test. The list of analyzed patients is included in the **[Supplementary Table 1](#T3){ref-type="table"}**. DPY19L2: dpy-19-like 2; SPATA16: spermatogenesis associated 16; PCK1: protein interacting with C kinase 1.](AJA-21-183-g004){#F4}

###### 

The list of analyzed patients in [Figure 4](#F4){ref-type="fig"}

  *Genes*                         *Nucleotide variants*   *Protein variants*   *Number of patients*   *Cohort size*                               *References*
  ------------------------------- ----------------------- -------------------- ---------------------- ------------------------------------------- ------------------------------------
  DPY19L2                         c.869G\>A               p.R290H              3                      34                                          *Hum Reprod* 2012; 27: 2549--58
  c.1024C.\>T                     p.Q342\*                                                                                                        
  c.1073T.\>A                     p.M358K                                                                                                         
  deletions                       23                                                                                                              
  c.1033C.\>T                     p.Q345X                 11                   64                     *Hum Mol Genet* 2012; 21: 3695--702         
  c.1478C.\>G                     p.T493R                                                                                                         
  c.2038A.T                       p.K680X                                                                                                         
  c.1183delT                      p.S395LfsX7                                                                                                     
  deletion                                                                                                                                        
  c.892C\>T                       p.R298C                                                                                                         
  c.1218+1G\>A                    \-                                                                                                              
  deletions                       20                                                                                                              
  c.1532delA                      p.K511RfsX8             5                    15                     *Mol Hum Reprod* 2013; 19: 395--404         
  c.1679delT, c.1681_1682delAC    p.L560X                                                                                                         
  c.869G\>A                       p.R290H                                                                                                         
  c.989T.\>C                      p.L330P                                                                                                         
  deletions                       4                                                                                                               
  c.1579_1580+4delAGGTAAinsTCAT                           3                    18                     *Mol Hum Reprod* 2016; 22: 35--45           
  c.892C\>T                       p.R298C                                                                                                         
  deletions                       11                                                                                                              
  not tested                      not tested              not tested           20                     *Am J Hum Genet* 2011; 88: 351--61          
  deletions                       15                                                                                                              
  not tested                      not tested              not tested           8                      *Am J Hum Genet* 2011; 88: 344--50          
  deletions                       7                                                                                                               
  c.2126+5G\>A                    \-                      4                    9                      The current study                           
  c.1720C\>T                      p.R574\*                                                                                                        
  c.1182_1184delATC               p.L394_S395delinsF                                                                                              
  c.368A\>G                       p.H123R                                                                                                         
  c.1182_1186delATCTT             p.L394FfsX19                                                                                                    
  c.1553_1554delAT                p.Y518CfsX14                                                                                                    
  deletions                       5                                                                                                               
  SAPAT16                         c.848G\>A               p.R283Q              3                      3                                           *Am J Hum Genet* 2007; 81: 813--20
  deletion of 22.6 Kb             \-                      2                    19                     *J Assist Reprod Genet* 2016; 33: 815--20   
  PICK1                           c.G198A                 p.G393R              1                      3                                           *Asian J Androl* 2010; 12: 556--60

### Treating the infertility of DPY19L2 variant-associated globozoospermic patients by ICSI with AOA {#sec3-10}

Finally, we wanted to evaluate the treatment of these DPY19L2 variant-associated globozoospermic patients. Because ICSI of globozoospermic spermatozoa may not be sufficient to overcome fertilization failure owing to a deficiency in oocyte activation capacity,[@ref29] we coupled ICSI with assisted oocyte activation (AOA) via calcium ionophore. ICSI with AOA was applied to five patients (P4--P8) at The Reproductive Medicine Center in The First Affiliated Hospital of Anhui Medical University, resulting in at least eight fertilized oocytes for each of the couples. Successful pregnancies and live birth were obtained for all the five couples (**[Table 3](#T4){ref-type="table"}**).

###### 

Results of intracytoplasmic sperm injection with assisted oocyte activation in patients with globozoospermia

                                                                                *P4*              *P5*              *P6*                    *P7*                  *P8*
  ----------------------------------------------------------------------------- ----------------- ----------------- ----------------------- --------------------- ---------------
  Male age (year)                                                               33                34                29                      25                    26
  Female age (year)                                                             28                24                27                      25                    27
  Oocytes retrieved (*n*)                                                       20                10                15                      14                    22
  Mature oocytes (MII) (*n*)                                                    16                9                 13                      13                    19
  Fertilized oocytes (*n*)                                                      10                8                 9                       9                     14
  D3 embryos (*n*)                                                              10                8                 9                       9                     14
  D5 embryos, *n* (embyo grade)                                                 2 (4BBX2,3BBX3)   2 (4BB,3BB)       4 (4AB,4BBX3,4BC,3BB)   4 (4BC,3AB,3BA,3BC)   2 (4BBX3,3BB)
  D6 embryos, *n* (embyo grade)                                                 0                 3 (4BB,4BB,4BC)   0                       0                     0
  Fresh embryos transferred, day of embryo (embryo grade)                       \-                D5(4BB,3BB)       \-                      D5(3BB,3BA)           \-
  Frozen embryos transferred in the first cycle, day of embryo (embryo grade)   D5(4BB,3BB)       D6(4BB,4BB)       D5(4AB,4BB)             D5(4BC,3BC)           D5(4BB,4BB)
  Livebirth, *n* (gender)                                                       1 (female)        2 (male)          2 (male)                1 (female)            1 (male)

AB, BA, BB, and BC indicate the quality of embryos classified by published grades[@ref27][@ref28]

DISCUSSION {#sec1-4}
==========

In the current study, we investigated a cohort of Chinese globozoospermic patients, who revealed high frequencies of *DPY19L2* mutations, either deletion or point mutations. Our results revealed partial deletion of the *DPY19L2* gene and identified six new variants, which might lead to the loss of function of DPY19L2.

Among the five new variants, two resulted in a premature stop codon, two led to amino acid substitutions, and one might lead to splicing defects of *DPY19L2* mRNA. P3 carries c.2126+5G\>A; this nucleotide substitution may lead to the alteration of the donor site in exon 21, most probably affecting splicing as predicted by Human Splicing Finder,[@ref30] and the mutant consensus value (CV) is 74.12, comparing to the WT 86.28. P3 contained a heterozygous variant of *DPY19L2*, which might lead to a dominant inactive form of DPY19L2. P6 carried a homozygous variant c.1720C\>T, leading to premature termination codon (PTC) in *DPY19L2* mRNA. The truncated DPY19L2 resulted in a large loss of protein after Ser574, which might disrupt its function in anchoring acrosome to the nuclear envelope. However, due to the lack of parental sequences for P6, it is possible that P6 contains one allele with c.1720C\>T, while the other allele is deleted. Regardless of the cause, both possibilities are harmful to DPY19L2 function. Because blood samples of P9\'s parents are unavailable, it is difficult to conclude whether the above two deletions are compound heterozygous mutations or not. By considering the essential function of DPY19L2 in globozoospermia and the typical results of biallelic *DPY19L2* variants, the two variants in P9 are probably compound heterozygous variants.

By analyzing all the point mutations, we found that these variants are likely enriched in certain regions, such as the 5^th^ and 6^th^ transmembrane domains. The 5^th^ transmembrane domain of the DPY19L2 protein contains three point mutations, including two nonsense mutations and one missense mutation. This suggests the importance of this transmembrane domain and also indicates that this region might be more fragile. The other variant-enriched region is the 6^th^ transmembrane domain, more specifically the 1182--1186 position on the cDNA sequence. Nucleotides in this region are frequently deleted in globozoospermic patients, which tend to cause frameshift (1183delT, 1182-1184delATC, and 1182-1186delATCTT). Although the number of the patients is limited, the distribution of these variants suggests the essential functions of these regions.

Numerous genes have been reported to be involved in sperm head shaping and related to globozoospermic phenotype, and *DPY19L2* is the most frequently mutated gene in globozoospermic patients.[@ref18] We noticed that in the reported cases, the frequency of *DPY19L2* variants in patients from Western countries was lower than that in Chinese patients. This discrepancy might arise from variability in data collection and analyses because some early studies only reported deletions, did not include point mutations, and did not perform WES for the globozoospermic patients without *DPY19L2* deletion. Considering the lacking *DPY19L2* point mutation data and the size of the cohort, the *DPY19L2* mutation frequency in Western countries should be comparable to that in Chinese globozoospermic patients, making the *DPY19L2* variant one of the major causes of globozoospermia globally.

If a spermatozoon lacks an acrosome, it cannot fertilize the oocyte, and the main technology to treat this syndrome is ICSI.[@ref31] Reports have suggested that the infertility of *DPY19L2* mutation-associated globozoospermia could be overcome by ICSI,[@ref26] but the overall fertilization rates remain low.[@ref32][@ref33][@ref34] The exact pathogenic mechanism for the deficiency in oocyte activation capacity is still unknown, but the mechanism is speculated to be associated with the sperm-associated oocyte-activating factor (SOAF), phospholipase C zeta (PLCζ), which may play a role in Ca^2+^ flux during fertilization.[@ref35] Some studies have shown that reduced amounts or abnormal forms of PLCζ may contribute to fertilization failure by ICSI with some infertile men, including those with globozoospermia.[@ref35][@ref36][@ref37] In addition, some studies have shown that PLCζ is absent or significantly decreased in globozoospermia.[@ref35] By using ICSI followed by AOA with calcium ionophore, higher fertilization rates were achieved which might be a result of the restored Ca^2+^ flux required for globozoospermic sperm--oocyte activation.[@ref38] Hence our results, together with previous studies, demonstrate that ICSI together with AOA is a very efficient way to treat the infertility of those globozoospermic patients with *DPY19L2* variants.

Many reported globozoospermic patients contain biallelic *DPY19L2* variants, indicating that *DPY19L2* variant-related globozoospermia is autosome recessively inherited.[@ref15][@ref16][@ref17][@ref18][@ref19] Hence, we suggest that the wife of the globozoospermic patient should be screened for possible *DPY19L2* variants to avoid the globozoospermic risk of the male babies after ICSI treatment. Moreover, the couple should be informed of the globozoospermic risk of their baby in the genetic counseling.
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